Combining tumor genomic and transcriptomic analysis with liquid biopsy ctDNA monitoring: analytical validation and clinical insights
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Comprehensive genomic profiling (CGP) is a time– and tissue-efficient method to help guide precision oncology. To enhance clinical utility of CGP, we investigated performance of a novel strategy integrating tumor DNA and mRNA profiling, together with liquid biopsy ctDNA monitoring.
Methods
Genomic DNA and mRNA simultaneously extracted from 604 archived tissue samples of 12 cancer types were used. Tumor DNA was subjected to targeted sequencing using a 504-gene panel with high-density probes (HDP), and shallow whole genome sequencing to profile genomic biomarkers. mRNA transcriptome profiling was performed to further capture fusion variants, and to predict tissue of origin (TOO) using our ensemble model OriCUP, an algorithm trained on 9,889 samples and independently validated on 731 samples. In a cohort of 55 metastatic lung cancer patients, longitudinal plasma ctDNA was analyzed using a hybrid tumor-informed and tumor-agnostic approach to predict progression-free survival (PFS).
Results
Among all biomarkers, DNA-sequencing using HDP achieved higher sensitivity than the standard panel design to identify copy number variations at chromosome-, gene– and exon-levels. The detection rate of fusion variants using DNA-sequencing alone was 20% lower than mRNA-sequencing in reference samples, while combination of both methods was essential to maximize fusion detection in clinical FFPE samples. For TOO, our OriCup model achieved prediction accuracy of 87.7% for primary tumors and 81.4% for metastatic tumors. In 55 lung cancer patients, ctDNA profiling identified additional 11.5% tumor-agnostic actionable and resistance mutations. Patients having more than 50% ctDNA decrease from baseline were classified as molecular responders, and showed significantly longer PFS than those classified as molecular non-responders (HR=9.42, 95% CI: 3.33-26.67, p<0.0001, 12-month PFS: 95.5% vs 31.7%).
Conclusions
Comprehensive genomic and transcriptomic profiling could reliably unveil genetic details not provided by DNA-only CGP. The integration of ctDNA detection further helped detect tumor-agnostic mutations and monitor treatment response.
